Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance and Pharmacokinetics of Danuglipron in Healthy Men
NCT04495140Phase 1Completed
- Sponsor
- Pfizer
- Start
- Jul 2020
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of danuglipron in type 2 diabetes mellitus (T2DM) and obesity (2 arms), sponsored by Pfizer. Primary endpoint: Total recovery of radioactivity in urine and feces at Day 14. Started Jul 2020; status: completed.
02
Drugs
danuglipron
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT04495140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04495140.